Stifel Financial’s PDL BioPharma, Inc. PDLI Stock Holding History

Stifel Financial’s Portfolio PDLI Stock Details PDLI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2014 Q3	–	Sell	-24,685	Closed	-$239K	–	2425
2014 Q2	$239K	Buy	24,685 +901	+4%	+$8.03K	﹤0.01%	1906
2014 Q1	$198K	Buy	+23,784	New	+$204K	﹤0.01%	1931

Other funds holding PDLI

ACM

Americafirst Capital Management Roseville, California $74M AUM 13.49% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Schroder Investment Management Group London, United Kingdom $122B AUM 29.27% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

AAM

Advisors Asset Management Monument, Colorado $6.01B AUM 24.74% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Stifel Financial's PDLI Position: Q3 2014 in Review

Stifel Financial sold out of PDL BioPharma, Inc. (PDLI) in Q3 2014, closing a stake of 24,685 shares — an estimated $239K sold.

Stifel Financial first reported a position in PDLI in Q1 2014 and held it in 2 quarters. The position peaked at $239K in Q2 2014. 231 funds tracked by Wall St. Rank hold PDLI as of Q3 2014.

Stifel Financial reported no remaining PDL BioPharma, Inc. position as of Q3 2014 after selling out during the quarter.
Stifel Financial sold 24,685 PDL BioPharma, Inc. shares in Q3 2014, an estimated $239K.
Stifel Financial first reported a position in PDL BioPharma, Inc. in Q1 2014 and held it in 2 quarters.
Stifel Financial's PDL BioPharma, Inc. position peaked at $239K in Q2 2014.
231 funds tracked by Wall St. Rank held PDL BioPharma, Inc. as of Q3 2014.

Based on Stifel Financial's 13F filing for Q3 2014, filed 13 Nov 2014.